Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2013-06-25 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming And Santarus Announce Poster Presentation Of Pivotal Clinical Data For Ruconest® (recombinant Human C1 Esterase Inhibitor)
Regulatory Filings Classification · 95% confidence The document is titled with company names (PHARMING and SANTARUS) and announces the presentation of clinical data for a drug (RUCONEST®) at a medical congress (EAACI & WAO World Allergy & Asthma Congress). It includes detailed tables summarizing primary endpoints and adverse events from a Phase III study, and discusses the status of the Biologics License Application (BLA) with the FDA. This format—a formal announcement detailing scientific/clinical progress and regulatory milestones, often issued by a company to the public/investors—is characteristic of a press release. Since there is no specific category for a general press release announcing clinical data or regulatory updates that isn't strictly an Earnings Release (ER) or a specific regulatory form (like 10-K), the most appropriate general category for this type of corporate communication, especially one detailing scientific findings and regulatory status updates, is the fallback category, Regulatory Filings (RNS), as it serves as a general announcement to the market.
2013-06-25 English
Pharming Elects To Redeem Fifth Tranche Of Convertible Bond For Cash
Capital/Financing Update Classification · 99% confidence The document is a press release announcing that Pharming Group NV has elected to redeem the fifth tranche of its convertible bond for cash, explicitly stating that no additional shares will be issued. This action directly relates to the company's capital structure, financing arrangements, and debt repayment, which falls under the scope of Capital/Financing Updates. The key phrases are 'REDEEM FIFTH TRANCHE OF CONVERTIBLE BOND FOR CASH' and 'NO ADDITIONAL SHARES ISSUED'. This is a specific corporate action related to financing, making 'CAP' the most appropriate classification over a general 'RNS' or 'LTR'. The document length is relatively short (3740 chars) but it is a direct announcement of the financing decision, not an announcement *about* a report.
2013-06-24 English
Pharming Confirms Completion Of Redemption Of Fourth Tranche Of Convertible Bond
Capital/Financing Update Classification · 98% confidence The document is a press release dated June 21, 2013, announcing the completion of the redemption of the fourth tranche of a convertible bond. It details a financing/capital structure event (redemption of debt) and confirms that no new shares were issued. This type of announcement, focusing on debt repayment and capital structure adjustments, aligns best with the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific financing action.
2013-06-21 English
Santarus And Pharming Announce FDA Acceptance For Review Of Ruconest (Recombinant Human C1 Esterase Inhibitor) Biologics License Application
Regulatory Filings Classification · 95% confidence The document is titled with company names and features a headline: "SANTARUS AND PHARMING ANNOUNCE FDA ACCEPTANCE FOR REVIEW OF RUCONEST (RECOMBINANT HUMAN C1 ESTERASE INHIBITOR) BIOLOGICS LICENSE APPLICATION". It is explicitly marked "For Immediate Release" and contains contact information typical of a press release. The content discusses the acceptance of a Biologics License Application (BLA) by the FDA and provides updates on clinical trials and regulatory timelines. This format strongly indicates an initial announcement of significant corporate or regulatory news, which aligns best with the definition of an Earnings Release (ER) if it were financial results, or more generally, a Regulatory Filing (RNS) or a specific announcement type. Since it is announcing a major regulatory milestone (FDA BLA acceptance) and is structured as a press release, it is not a full report (like 10-K or IR). It is not a Call Transcript (CT), Management Discussion (MDA), or Investor Presentation (IP). Given the nature of announcing a regulatory event, it fits best under the general Regulatory Filings (RNS) category, as it is a public announcement of a regulatory event, although it shares characteristics with an Earnings Release in its immediate nature. However, since it is not reporting financial results (like revenue/net income), RNS is the most appropriate general regulatory announcement category, or potentially a Capital/Financing Update (CAP) if the milestone payment was the focus, but the focus is regulatory acceptance. I will classify it as RNS as a general regulatory announcement.
2013-06-18 English
Pharming Announces New Data On Ruconest In Primate Model Of Delayed Graft Function (DGF)
Regulatory Filings Classification · 95% confidence The document is a press release from Pharming Group NV announcing new data regarding their drug RUCONEST® presented at the American Transplant Congress. It details scientific findings, provides background on the drug and the company, and includes contact information. This format—an announcement of recent developments, data presentation, or corporate news that is not a full financial report (like 10-K or IR) or a formal regulatory filing like a proxy statement—best fits the category for general corporate news or announcements. Since it is not a transcript (CT), a formal earnings release (ER), or a specific management discussion (MDA), and it is announcing scientific/clinical progress, it is most closely aligned with a general regulatory announcement or news release. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, non-financial corporate announcements that are released to the public/market, although 'Investor Presentation' (IP) might seem close, this is a press release *about* data presented, not the presentation itself. I will classify it as RNS as it is a general market announcement.
2013-05-23 English
Pharming confirms completion of redemption of 3rd tranche and the redemption of 4th tranche of convertible bond
Capital/Financing Update Classification · 99% confidence The document announces the completion of the redemption of the third and fourth tranches of a convertible bond, detailing the issuance of shares to bondholders as payment. This involves changes to the company's capital structure (issuance of new shares to settle debt) and financing activities. This aligns best with the 'Capital/Financing Update' category (CAP), as it is a specific announcement about debt settlement via equity issuance, rather than a general earnings release (ER) or a comprehensive interim report (IR). It is not a proxy statement (PSI), dividend notice (DIV), or director dealing report (DIRS).
2013-05-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.